You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

160 Results
Regimen
Cancer Type:
Lung, 
Mesothelioma (Pleural)
Intent: Palliative
Jun 2021
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Adjuvant
Jun 2021
Regimen
Cancer Type:
Sarcoma, 
Soft Tissue
Intent: Palliative
Funding:
ODB - General Benefit
    temozolomide
Jun 2021
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Intent: Curative
Funding:
ODB - General Benefit
    dexamethasone
Apr 2022
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade
Intent: Curative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Aggressive Histology Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - HIV-Related Aggressive Histology B-cell Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Aggressive Histology Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - HIV-Related Aggressive Histology B-cell Lymphoma
ODB - General Benefit
    dexamethasone
Apr 2022
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade
Intent: Palliative
May 2022
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Intent: Curative
Funding:
ODB - General Benefit
    dexamethasone
Apr 2022
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade
Intent: Curative
May 2022
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Jun 2021
Drug
Other Name(s): Oncaspar®
Dec 2022
Regimen
Cancer Type:
Hematologic, 
Lymphoma - T-cell
Intent: Curative
Funding:
New Drug Funding Program
    Pegaspargase - Extranodal Natural Killer/T-cell Lymphoma
ODB - General Benefit
    dexamethasone
Jan 2022
Regimen
Cancer Type:
Lung, 
Mesothelioma (Pleural)
Intent: Palliative
Jun 2021

Pages